Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lise M. van Wijk"'
Autor:
Lise M. van Wijk, Claire J. H. Kramer, Sylvia Vermeulen, Natalja T. ter Haar, Marthe M. de Jonge, Judith R. Kroep, Cor D. de Kroon, Katja N. Gaarenstroom, Harry Vrieling, Tjalling Bosse, Maaike P. G. Vreeswijk
Publikováno v:
Cancers, Vol 13, Iss 12, p 2994 (2021)
PARP inhibitor (PARPi) sensitivity is related to tumor-specific defects in homologous recombination (HR). Therefore, there is great clinical interest in tests that can rapidly and reliably identify HR deficiency (HRD). Functional HRD tests determine
Externí odkaz:
https://doaj.org/article/5c7e5eef71a44a0eac94c873b0137992
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
Autor:
Lise M. van Wijk, Sylvia Vermeulen, Matty Meijers, Manuela F. van Diest, Natalja T. ter Haar, Marthe M. de Jonge, Nienke Solleveld-Westerink, Tom van Wezel, Dik C. van Gent, Judith R. Kroep, Tjalling Bosse, Katja N. Gaarenstroom, Harry Vrieling, Maaike P. G. Vreeswijk
Publikováno v:
Cancers, Vol 12, Iss 10, p 2805 (2020)
Recent studies have shown that the efficacy of PARP inhibitors in epithelial ovarian carcinoma (EOC) is related to tumor-specific defects in homologous recombination (HR) and extends beyond BRCA1/2 deficient EOC. A robust method with which to identif
Externí odkaz:
https://doaj.org/article/330d37fda87941d7988c9f7ebb46b4ce
Autor:
Tjalling Bosse, Maaike P.G. Vreeswijk, Alexandra Leary, Etienne Rouleau, Cor D. de Kroon, Yannick Boursin, Bastien Job, Harry Vrieling, David N. Church, Mark A. Glaire, Remi A. Nout, Vincent T.H.B.M. Smit, Natalja T. ter Haar, Matty Meijers, Philip C. Schouten, Lise M. van Wijk, Aurélie Auguste, Marthe M. de Jonge
Supplementary Material and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17d9d1e6d547375ed6a6fe0b5b87a231
https://doi.org/10.1158/1078-0432.22468142
https://doi.org/10.1158/1078-0432.22468142
Autor:
Tjalling Bosse, Maaike P.G. Vreeswijk, Alexandra Leary, Etienne Rouleau, Cor D. de Kroon, Yannick Boursin, Bastien Job, Harry Vrieling, David N. Church, Mark A. Glaire, Remi A. Nout, Vincent T.H.B.M. Smit, Natalja T. ter Haar, Matty Meijers, Philip C. Schouten, Lise M. van Wijk, Aurélie Auguste, Marthe M. de Jonge
Purpose:The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination defic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff2fda19256b3d5f75f17c7ebe98757
https://doi.org/10.1158/1078-0432.c.6526850.v1
https://doi.org/10.1158/1078-0432.c.6526850.v1
Autor:
Tjalling Bosse, Maaike P.G. Vreeswijk, Alexandra Leary, Etienne Rouleau, Cor D. de Kroon, Yannick Boursin, Bastien Job, Harry Vrieling, David N. Church, Mark A. Glaire, Remi A. Nout, Vincent T.H.B.M. Smit, Natalja T. ter Haar, Matty Meijers, Philip C. Schouten, Lise M. van Wijk, Aurélie Auguste, Marthe M. de Jonge
Figure S1 shows that the Oncoscan and CGH agilent platform yield similar results.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a0c87cfd751bf45c1d1b144c1ed9b57
https://doi.org/10.1158/1078-0432.22468148
https://doi.org/10.1158/1078-0432.22468148
Autor:
Tjalling Bosse, Maaike P.G. Vreeswijk, Alexandra Leary, Etienne Rouleau, Cor D. de Kroon, Yannick Boursin, Bastien Job, Harry Vrieling, David N. Church, Mark A. Glaire, Remi A. Nout, Vincent T.H.B.M. Smit, Natalja T. ter Haar, Matty Meijers, Philip C. Schouten, Lise M. van Wijk, Aurélie Auguste, Marthe M. de Jonge
Table S1 shows the clinicopathological characteristics of the cases included in final analysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478ebbf175a1a412e395f325e3a52f47
https://doi.org/10.1158/1078-0432.22468139.v1
https://doi.org/10.1158/1078-0432.22468139.v1
Autor:
Katja N. Gaarenstroom, Claire J H Kramer, Lise M van Wijk, Tjalling Bosse, Harry Vrieling, Cor D. de Kroon, Judith R. Kroep, S. Vermeulen, Marthe M de Jonge, Natalja T. ter Haar, Maaike P.G. Vreeswijk
Publikováno v:
Cancers, 13(12), 2994. MDPI} {AG
Cancers
Cancers, Vol 13, Iss 2994, p 2994 (2021)
Cancers
Cancers, Vol 13, Iss 2994, p 2994 (2021)
Simple Summary Rapid and reliable identification of patients with homologous recombination deficient (HRD) tumors is important for treatment choice as these tumors tend to respond well to platinum-based chemotherapy and PARP inhibitors (PARPi). In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91077617985b09704101321a36dda3c2
https://hdl.handle.net/1887/3250622
https://hdl.handle.net/1887/3250622
Autor:
Lise M van Wijk, Cor D. de Kroon, Tjalling Bosse, Harry Vrieling, Claire J H Kramer, Natalja T. ter Haar, S. Vermeulen, Maaike P.G. Vreeswijk, Katja N. Gaarenstroom, Violeta Serra, Marthe M de Jonge
Publikováno v:
Cancer Research. 81:364-364
Sensitivity to PARP inhibitors is related to tumor-specific defects in homologous recombination (HR) and extends beyond BRCA1/2-related deficiencies. Therefore, there is great interest in a robust method to identify HR-deficient (HRD) carcinomas in r
Autor:
Jose Espejo Valle-Inclan, Victor W.H. Ho, Nizar Hami, Markus J. van Roosmalen, Benjamin G. Neel, Kadi Lõhmussaar, Anjali Vanita Balgobind, Lennart Kester, Ronald P. Zweemer, Harry Begthel, Harry Vrieling, Jeroen Korving, Tjalling Bosse, Chris J. de Witte, Maaike P.G. Vreeswijk, Oded Kopper, Wigard P. Kloosterman, Natalie Proost, Alexander van Oudenaarden, Marieke van de Ven, Paul J. van Diest, Rebecca Theeuwsen, Bas Ponsioen, Johannes L. Bos, Hugo J. Snippert, Katja N. Gaarenstroom, Lise M van Wijk, Trudy N. Jonges, Hans Clevers, Petronella O. Witteveen, Sonia Aristín Revilla
Publikováno v:
Nature Medicine, 25(5), 838-849. Nature Publishing Group
Nature Medicine, 25(5), 838. Nature Publishing Group
Nature Medicine, 25(5), 838-+. NATURE PUBLISHING GROUP
Nature Medicine, 25(5), 838. Nature Publishing Group
Nature Medicine, 25(5), 838-+. NATURE PUBLISHING GROUP
Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are limited and hard to establish. We present a protocol that enables e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::628ba460dc571b7d280acb944303af20
https://pure.knaw.nl/portal/en/publications/45c50205-416f-43d2-984d-0d6a6541c128
https://pure.knaw.nl/portal/en/publications/45c50205-416f-43d2-984d-0d6a6541c128
Autor:
Yannick Boursin, Matty Meijers, Remi A. Nout, Marthe M de Jonge, Bastien Job, Aurélie Auguste, Etienne Rouleau, David N. Church, Vincent T.H.B.M. Smit, Tjalling Bosse, Mark A. Glaire, Harry Vrieling, Philip C. Schouten, Maaike P.G. Vreeswijk, Alexandra Leary, Natalja T. ter Haar, Cornelis D. de Kroon, Lise M van Wijk
Publikováno v:
Clinical Cancer Research, 25(3), 1087-1097
Purpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination defi